RxDoctor Payments Data

William Wilkinson, MD

Ophthalmology · Pontiac, MINPI 1124057690

Payments from drug & device makers

$2,161in general payments, 2019–2025

Across 127 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$701
  • AbbVie$220
  • Sun Pharmaceutical Industries Inc.$199
  • Rxsight Inc$161
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$148
  • Alcon$132
  • plus $599 from 14 others

What the payments were for

  • Food & beverage$2,13199%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,161 in reported general payments places this provider in the 60th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$359,929
Medicare patients
1,287
Services billed
2,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine83$95,548
Cyclosporine107$68,520
LumiganBimatoprost94$51,856
RocklatanNetarsudil Mesylat/Latanoprost53$29,705
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol87$22,538
Loteprednol Etabonate101$22,321
Prednisolone Acetate229$17,503
Latanoprost792$17,441
Restasis MultidoseCyclosporine16$15,904
Brimonidine Tartrate106$13,951
Fluorometholone76$7,023
CequaCyclosporine12$6,773
Alphagan PBrimonidine Tartrate13$6,306
Ketorolac Tromethamine199$5,806
SimbrinzaBrinzolamide/Brimonidine Tart21$4,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P$220$169,615206 claims
Aerie Pharmaceuticals, Inc.Rocklatan$41$29,70553 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$148$22,321101 claims
Sun Pharmaceutical Industries Inc.Cequa$199$6,77312 claims
AlconSimbrinza$132$4,77521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →